Sarah Davis, MD
Family Medicine · Sewell, NJNPI 1548618739
Payments from drug & device makers
Across 298 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$797
- AbbVie$778
- Pfizer$553
- AstraZeneca$417
- GSK$320
- Lilly USA, LLC$256
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,750100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $797 |
| AbbVie | 55 | $778 |
| Pfizer | 28 | $553 |
| AstraZeneca | 21 | $417 |
| GSK | 23 | $320 |
| Lilly USA, LLC | 16 | $256 |
| Abbott | 8 | $180 |
| Astellas Pharma US Inc | 12 | $180 |
| Bayer | 8 | $160 |
| Boehringer Ingelheim | 10 | $148 |
| Axsome Therapeutics, Inc. | 6 | $110 |
| Amgen | 6 | $96 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Exact Sciences | 4 | $70 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Novartis | 4 | $66 |
| Merck | 4 | $54 |
| Amarin Pharma, Inc. | 4 | $48 |
| Currax Pharmaceuticals LLC | 2 | $40 |
| Lundbeck LLC | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Johnson & Johnson | 2 | $30 |
| Spectrum Pharmaceuticals Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 2 | $23 |
| Neotract Inc. | 1 | $22 |
| Medtronic | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 2 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $14 |
| W. L. Gore & Associates, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAXLOVID$110
How this compares
$4,750 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 61 | $64,135 |
| EliquisApixaban | 60 | $55,312 |
| JanuviaSitagliptin Phosphate | 45 | $45,422 |
| RexultiBrexpiprazole | 26 | $42,843 |
| RybelsusSemaglutide | 30 | $42,416 |
| OzempicSemaglutide | 40 | $41,277 |
| TrulicityDulaglutide | 21 | $39,164 |
| FarxigaDapagliflozin Propanediol | 16 | $22,586 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,550 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $15,393 |
| MyrbetriqMirabegron | 14 | $14,179 |
| LinzessLinaclotide | 18 | $11,341 |
| Duloxetine Hcl | 77 | $9,294 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $5,495 |
| Atorvastatin Calcium | 456 | $5,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $797 | $83,69470 claims |
| Boehringer IngelheimJardiance | $148 | $64,13561 claims |
| PfizerEliquis | $553 | $55,31260 claims |
| MerckJanuvia | $54 | $45,42245 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $84 | $42,84326 claims |
| Lilly USA, LLCTrulicity | $256 | $39,16421 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $320 | $36,94350 claims |
| AstraZenecaFarxiga | $417 | $22,58616 claims |
| Astellas Pharma US IncMyrbetriq | $180 | $14,17914 claims |
| AbbVieLinzess, Synthroid | $778 | $12,64342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Sewell
- Jennifer CaudleSewell$226K
- Robert VenutiSewell$14K
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.